Crossmark

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

Crossref DOI link: https://doi.org/10.1186/s12610-018-0074-2

Published Online: 2018-07-18

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Asakawa, Jumpei

Iguchi, Taro

Tamada, Satoshi https://orcid.org/0000-0002-7102-3408
Yasuda, Sayaka

Ninomiya, Noriko

Kato, Minoru

Yamasaki, Takeshi

Ohmachi, Tetusji

Nakatani, Tatsuya
License Information

Text and Data Mining valid from 2018-07-18
More Information

Article History

Received: 25 February 2018

Accepted: 24 May 2018

First Online: 18 July 2018

Ethics approval and consent to participate

: Permission to access the database for a review of the medical records of these patients was obtained from the Local Research Ethics Committee at Osaka City University (approval number 4011).

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below